This work was funded by the British Heart Foundation (PG/15/40/31522), Alzheimer Research UK (ARUK-PG2017A-3), and European Research Council (#10102507) grants to G. Pula.

The collection of peripheral blood from consenting volunteers is approved by the local Ethics Committee and the National Health Service Health Research Authority (REC reference: 21/SC/0215; IRAS ID: 283854).
1. Method 1: Superoxide anion detection using DHE by flow cytometry
<ol>
	<li>Pre-warm (37 &#176;C) sodium citrate solution (4% w/v) and use it as an anti-coagulant by adding it directly to the blood at the time of venepuncture at a ratio of 1:7 (0.5% w/v final).</li>
	<li>Draw peripheral human blood from healthy volunteers by median cubital vein venepuncture.</li>
	<li>Obtain platelet-rich plasma (PRP) from whole blood by an initial centrifugation step at 200 x g for 20 min.</li>
	<li>Centrifuge PRP at 500 x g for 10 min with the reversible platelet inhibitors indomethacin (10 &#181;M) and PGE1 (40 ng/mL).</li>
	<li>Resuspend the resulting platelet pellet in modified Tyrode&#39;s buffer (145 mM NaCl, 2.9 mM KCl, 10 mM 4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid (HEPES),&#160;1 mM MgCl2, 5 mM glucose, pH 7.3) (37 &#176;C) at a density of 2 x 108 platelets/mL.</li>
	<li>After isolation, rest platelets for 30 min at 37 &#176;C.</li>
	<li>Prepare DHE in dimethyl sulfoxide (DMSO) at a stock concentration of 5 mM.</li>
	<li>Add DHE to the platelet suspension at 5 &#181;M final concentration (dilute the stock solution 1 to 1,000, with final DMSO concentration 0.1% v/v) and incubate for 15 min at 37 &#176;C.</li>
	<li>Treat platelets with pharmacological agents and/or ROS scavengers for 15 min before stimulation with the desired physiological stimuli and concentrations (e.g., 0.1 unit/mL thrombin or 3 &#181;g/mL collagen).</li>
	<li>After stimulation, dilute platelet suspensions 1 to 10 in ice-cold modified HEPES buffer.</li>
	<li>For the flow cytometry, set side scattering (SSC) and forward scattering (FSC) gain at 40 mV and 220 mV, respectively, and use logarithmic scale scatter plots to visualize the particle population in the suspension (example in Figure 1A).</li>
	<li>(OPTIONAL) Immunostain one aliquot of platelet suspension using an anti-CD41 antibody to identify the population of events corresponding to platelets (example in Figure 1B).</li>
	<li>Analyse samples by flow cytometry using excitation at 405 nm (violet laser) and emission at 580 nm wavelength, which selectively detects the superoxide anion-specific product 2-hydroxy-ethidium (2OH-Et+) (Figure 2). 
	NOTE: Fixation with paraformaldehyde and long-term sample storage are not advisable.</li>
</ol>
2. Method 2: Superoxide anion detection using DHE by single-platelet fluorescence imaging
<ol>
	<li>Coat an 8-well &#181;-slide on the day of the experiment with 0.1 mg/mL fibrillar collagen I from equine tendons (Horm collagen), 0.2 mg/mL fibrinogen or 1 mg/mL poly-L-lysine (PLL) in modified Tyrode&#39;s buffer for 2 h at 37 &#176;C.</li>
	<li>Wash twice with modified Tyrode&#39;s buffer (10 min each).</li>
	<li>Quench non-specific adhesion by incubation in modified Tyrode&#39;s buffer plus 5 mg/mL bovine serum albumin (BSA) for a minimum of 30 min (or until the experiment).</li>
	<li>Pre-warm (37 &#176;C) sodium citrate solution (4% w/v) and use it as an anti-coagulant by adding it directly to the blood at the time of venepuncture at a ratio of 1:7 (0.5% w/v final).</li>
	<li>Draw peripheral human blood from healthy volunteers by median cubital vein venepuncture.</li>
	<li>Obtain platelet-rich plasma (PRP) from whole blood by an initial centrifugation step at 200 x g for 20 min.</li>
	<li>Centrifuge PRP at 500 x g for 10 min with the reversible platelet inhibitors indomethacin (10 &#181;M) and PGE1 (40 ng/mL).</li>
	<li>Resuspend the resulting platelet pellet in modified Tyrode&#39;s&#160;buffer (145 mM NaCl, 2.9 mM KCl, 10 mM HEPES, 1 mM MgCl2, 5 mM glucose, pH 7.3) (37 &#176;C) at a density of 4 x 107 platelets/mL.</li>
	<li>After isolation, rest platelets for 30 min at 37 &#176;C.</li>
	<li>Prepare DHE in dimethyl sulfoxide (DMSO) at a stock concentration of 10 mM.</li>
	<li>Add DHE at 10 &#181;M final concentration to the platelet suspension (dilute the stock solution 1 to 1,000, with final DMSO concentration 0.1% v/v) and incubate for 1 min (37 &#176;C).</li>
	<li>After the 1 min of incubation with DHE, remove the blocking solution from the chosen wells, position the &#181;-slide on the microscope stage ready for imaging, and gently dispense platelets.</li>
	<li>Monitor DHE conversion to 2OH-Et+ by inverted confocal imaging for 10 min (405/580 nm ex/em), with images collected every 10 s with a 40x oil immersion lens.</li>
	<li>(OPTIONAL) For wells coated with PLL, monitor the superoxide anion generation in response to a soluble agonist (e.g., 0.1 unit/mL thrombin or 3 &#181;g/mL collagen) by adding the agonist 10 min after platelet dispensing and fluorescence image collection for a further 10 min, as described in step 2.13.</li>
	<li>(OPTIONAL) If required, add superoxide anion scavengers or selective inhibitors (e.g., NOX inhibitor) by dispensing gently to the side of the well during the time course and collect fluorescence images as described in 2.13 for a further 10 min.</li>
	<li>Quantify single-cell fluorescence analysis by selecting the Region of Interest (ROI) containing representative single platelets and analyzing fluorescence intensity in different frames with the Measure tool of imaging suite ImageJ 1.53t.</li>
</ol>
3. Method 3: Detection of superoxide anion by platelets using electron paramagnetic resonance (EPR)
<ol>
	<li>Pre-warm (37 &#176;C) sodium citrate solution (4% w/v) and use it as an anti-coagulant by adding it directly to the blood at the time of venepuncture at a ratio of 1:7 (0.5% w/v final).</li>
	<li>Draw peripheral human blood from healthy volunteers by median cubital vein venepuncture.</li>
	<li>Obtain platelet-rich plasma (PRP) from whole blood by an initial centrifugation step at 200 x g for 20 min.</li>
	<li>Centrifuge PRP at 500 x g for 10 min with the reversible platelet inhibitors indomethacin (10 &#181;M) and PGE1 (40 ng/mL).</li>
	<li>Resuspend the resulting platelet pellet in modified Tyrode&#39;s&#160;buffer (145 mM NaCl, 2.9 mM KCl, 10 mM HEPES, 1 mM MgCl2, 5 mM glucose, pH 7.3) (37 &#176;C) at a density of 2 x 108 platelets/mL.</li>
	<li>After isolation, rest platelets for 30 min at 37 &#176;C.</li>
	<li>Add 5 &#181;M diethyldithiocarbamate (DETC) and 25 &#181;M deferoxamine to the platelet suspension.</li>
	<li>Without incubation, add 200 &#181;M 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH).</li>
	<li>Load samples onto the aggregometer within aggregation cuvettes (including Teflon-coated stirring magnets).</li>
	<li>After 1 min, add the stimuli at the desired concentration (e.g., 1 unit/mL thrombin or 3 &#181;g/mL collagen). Incubate for 10 min.</li>
	<li>(OPTIONAL) Obtain superoxide anion generation at different time points by proceeding to step 3.12 at the desired time.</li>
	<li>Transfer the platelet suspension from the aggregation cuvette to a microcentrifuge tube and quickly spin down at 6,000 x g for 10 s.</li>
	<li>Load 50 &#181;L of the supernatant in capillary micropipettes and seal with EPR&#160;sealing wax.</li>
	<li>Transfer samples to the EPR scanner.</li>
	<li>Set the EPR scanner as follows: center field 3,492.5 G, field sweep 60 G, modulation amplitude 2 G, sweep time 10 s, number of scans 10, microwave frequency 9.39 GHz, microwave power 20 mW, conversion time 327.68 ms, time constant 5242.88 ms.</li>
	<li>Estimate CMH oxidation to CM&#9679; as the area under the curve (AUC) of the EPR peaks recorded using the above parameters.</li>
	<li>Build a calibration curve plotting the EPR intensity measured as described in step 3.16 on the y-axis and&#160;the concentrations of the commercially available CM&#9679; on the x-axis (e.g., 0, 0.3, 1, 3, 10, and 30 &#181;M).</li>
	<li>From the CM&#9679; concentration in the samples, obtain the amount of superoxide anion generated by the platelets in the samples using the formulas described in the Representative Results section.</li>
</ol>

Detection of Superoxide Anion in Platelets Using Fluorescence Imaging and EPR

The authors have nothing to disclose.

In this manuscript, we present three different techniques with the potential to advance the capability to investigate the redox-dependent regulation of platelet function via the selective detection of O2&#8226;-. The first two methods are an improvement on existing techniques because of the redox probe utilized (DHE instead of the more common but less reliable DCFDA). These techniques are, therefore, easily accessible, and most laboratories can adopt them effectively without particular eq...

The superoxide anion (O2&#8226;-) is the most functionally relevant ROS generated in platelets1. O2&#8226;- is the product of the reduction of molecular oxygen and the precursor of many different ROS 2. The dismutation of O2&#8226;- leads to the generation of hydrogen peroxide (H2O2) via spontaneous reactions in aqueous solution or reactions catalyzed by superoxide dismutases (SODs3). Although different enzymatic sources have been suggested (e.g., xanthine oxidase4, lipoxygenase5, cyclooxygenase6, and nitric oxide synthase7), mitochondrial respiration8,9 and nicotinamide adenine dinucleotide phosphate-oxidases (NOXs)10 are the most prominent sources of superoxide anion in eukaryotic cells. This also seems to be the case in platelets, where electron leakage from mitochondrial respiration11,12 and the enzymatic activity of NOXs13,14 have been described as the main contributors to the superoxide anion output.
Although several studies have focused on the regulation of platelets by O2&#8226;-, there is no consensus regarding the molecular mechanisms responsible. The modulation of surface receptor activity via direct oxidation and disulfide bond formation has been proposed for different platelet receptors. The positive regulation of integrin &#945;IIb&#946;3 by ROS via direct oxidation of cysteine residues has been suggested15,16,17. Similarly, since platelet responses to collagen depend on disulfide-dependent dimerization and consequent dimerization of the glycoprotein VI (GPVI)18, receptor activity potentiation by ROS-dependent oxidation has been proposed19, although not fully proven experimentally. Finally, ROS-induced oxidation of the sulfhydryl groups of glycoprotein Ib (GPIb) was shown to promote platelet adhesion and platelet-leukocyte interaction during inflammation20. Conversely, as a possible consequence of decreased sulfhydryl group oxidation and receptor activation, the shedding of the ectodomain of both GPVI and GPIb is diminished&#160;by reducing conditions21.
Modes of action independently of a direct oxidation of platelet surface receptors have also been proposed. ROS, including O2&#8226;-, have been shown to positively modulate the collagen receptor GPVI by attenuating the activity of the Src homology region 2-containing protein tyrosine phosphatase 2 (SHP-2), which negatively regulates the signaling cascade of this receptor22. Moreover, O2&#8226;- can generate ONOO- (peroxynitrite) by rapid reaction with nitric oxide (NO), which normally inhibits platelets through the NO-sensitive guanylyl cyclase (NO-GC) and the generation of the negative platelet regulator cyclic GMP (cGMP)23,24. The resulting decrease in NO levels can lead to platelet potentiation. Alternatively, the generation of O2&#8226;- by NOX2 has been suggested to contribute to lipid peroxidation and isoprostane formation, which is essential for platelet activation and adhesion25. Finally, mitogen-activated protein kinase (MAPK) extracellular signal-regulated kinase 5 (ERK5), a protein kinase proposed as a redox stress sensor in platelets26, is activated by O2&#8226;- and induces a procoagulant phenotype in platelets (as estimated by flow cytometry-based measurement of phosphatidylserine externalization)27.
The dysregulation of O2&#8226;- and other ROS generation in platelets has been associated with the exaggerated hemostatic response leading to thrombotic cardiovascular complications associated with atherosclerosis, diabetes mellitus, hypertension, obesity, and cancer28,29. In these pathological settings, the ROS output by platelets is increased, which leads to a potentiation of their adhesive and aggregatory responses. In addition to the effect on platelet responses, the free radical output of platelets may have consequences on other blood cells and vascular structures, which is a poorly understood and underinvestigated area of cardiovascular health30. Despite our limited understanding of the molecular mechanisms linking oxidative stress to thrombotic conditions, the clinical relevance of antioxidants for the protection against cardiovascular disease has received considerable attention. Plasma antioxidant levels have been shown to inversely correlate with the risk of developing cardiovascular conditions, and dietary antioxidant consumption has been shown to protect against coronary artery disease31,32.&#160;Consequently, the use of dietary antioxidants has been advocated as a promising approach for cardiovascular disease prevention33,34,35. Amongst the effects of ROS generation in platelets, the increase in apoptosis can have important pathophysiological effects36,37. Overall, reliable protocols to detect and quantify the O2&#8226;- output by platelets are increasingly relevant in cardiovascular research.
Currently, available techniques for the detection of ROS have important limitations of specificity (i.e., the chemical nature of the oxidant molecules detected is unknown) and reliability (i.e., the unwanted interaction with biological molecules and experimental reagents leads to biased non-physiological results)38,39. The most commonly used approach for the detection of ROS in platelets is based on the use of dichlorodihydrofluorescein diacetate (DCFDA), which is converted to dichlorodihydrofluorescein (DCFH) by intracellular esterases and consequently to the highly fluorescent dichlorofluorescein (DCF) by cellular oxidants, including hydroxyl radicals and peroxidase-H2O2 intermediates40,41. Despite its wide use, serious questions have been raised regarding the reliability of this approach for the measurement of intracellular ROS38. The oxidation of DCFH to DCF can be, in fact, induced by transition metal ions (e.g., Fe2+) or heme-containing enzymes (e.g., cytochromes) instead of ROS42. Moreover, DCFDA is converted by cell peroxidases to its semiquinone free radical form (DCF&#8226;-), which is in turn oxidized to DCF by reaction with molecular oxygen (O2) with the release of O2&#8226;-, which leads to the artificial amplification of oxidative responses41,43,44. Therefore, the detection of intracellular ROS by DCFDA is useful for obtaining initial insights but requires cautious consideration and extensive experimental controls38,39.
This study presents three alternative techniques for the detection and measurement of the key regulator of platelet function O2&#8226;-1. The first technique is the detection using DHE and flow cytometry, which offers advantages of reliability and specificity over DCFDA. The second technique proposed here also utilizes DHE, but the detection method is live-platelet fluorescence imaging, which allows the study of the generation of O2&#8226;-&#160;upon platelet signaling with fast kinetics and single-cell resolution. Finally, a protocol based on the use of the hydroxylamine spin probe 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH) in EPR resonance experiments offers the possibility of quantifying the rate of O2&#8226;- generation by platelets and comparing it in different conditions.

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH)</td>
			<td>Noxygen Science trasfer and Diagnostics GmbH</td>
			<td>NOX-02.1-50mg</td>
			<td>Reagent for EPR (spin probe)</td>
		</tr>
		<tr>
			<td>BD FACSAria III</td>
			<td>BD Biosciences&#160;</td>
			<td>NA</td>
			<td>Flow cytometer</td>
		</tr>
		<tr>
			<td>Bovine Serum Albumin</td>
			<td>Merck/Sigma</td>
			<td>A7030</td>
			<td>For &#956;-slide coating</td>
		</tr>
		<tr>
			<td>Bruker E-scan M (Noxyscan)</td>
			<td>Noxygen Science trasfer and Diagnostics GmbH</td>
			<td>&#160;NOX-E.11-BES&#160;</td>
			<td>EPR spectrometer</td>
		</tr>
		<tr>
			<td>Catalase&#8211;polyethylene glycol (PEG-Cat.)</td>
			<td>Merck/Sigma</td>
			<td>C4963</td>
			<td>Hydrogen peroxide scavenger (specificity control)</td>
		</tr>
		<tr>
			<td>ChronoLog Model 490+4</td>
			<td>Labmedics/Chronolog</td>
			<td>NA</td>
			<td>Aggregometer</td>
		</tr>
		<tr>
			<td>CM radical</td>
			<td>Noxygen Science trasfer and Diagnostics GmbH</td>
			<td>NOX-20.1-100mg&#160;</td>
			<td>Reagent for EPR (calibration control)</td>
		</tr>
		<tr>
			<td>deferoxamine&#160;</td>
			<td>Noxygen Science trasfer and Diagnostics GmbH</td>
			<td>NOX-09.1-100mg&#160;</td>
			<td>Reagent for EPR</td>
		</tr>
		<tr>
			<td>diethyldithiocarbamate (DETC)&#160;</td>
			<td>Noxygen Science trasfer and Diagnostics GmbH</td>
			<td>NOX-10.1-1g&#160;</td>
			<td>Reagent for EPR</td>
		</tr>
		<tr>
			<td>Dihydroethidium</td>
			<td>Thermo Fisher Scientifics</td>
			<td>D11347</td>
			<td>Superoxide anion probe</td>
		</tr>
		<tr>
			<td>Dimethyl sulfoxide</td>
			<td>Merck/Sigma</td>
			<td>34869</td>
			<td>For stock solution preparation&#160;</td>
		</tr>
		<tr>
			<td>EPR sealing wax plates</td>
			<td>Noxygen Science trasfer and Diagnostics GmbH</td>
			<td>NOX-A.3-VPM</td>
			<td>Consumable for EPR</td>
		</tr>
		<tr>
			<td>EPR-grade water</td>
			<td>Noxygen Science trasfer and Diagnostics GmbH</td>
			<td>NOX-07.7.1-0.5L&#160;</td>
			<td>Reagent for EPR</td>
		</tr>
		<tr>
			<td>Fibrinogen from human plasma</td>
			<td>Merck/Sigma</td>
			<td>F4883</td>
			<td>For &#956;-slide coating</td>
		</tr>
		<tr>
			<td>FITC anti-human CD41 Antibody</td>
			<td>BioLegend</td>
			<td>303704</td>
			<td>Platelet-specific staining for flow cytometry</td>
		</tr>
		<tr>
			<td>Glass cuvettes&#160;</td>
			<td>Labmedics/Chronolog</td>
			<td>P/N 312</td>
			<td>Consumable for incubation in aggregometer</td>
		</tr>
		<tr>
			<td>Horm Collagen</td>
			<td>Labmedics/Chronolog</td>
			<td>P/N 385</td>
			<td>For platelet stimulation</td>
		</tr>
		<tr>
			<td>ImageJ&#160;</td>
			<td>National Institutes of Health (NIH)</td>
			<td>NA</td>
			<td>ImageJ 1.53t (Wayne Rasband)</td>
		</tr>
		<tr>
			<td>Indomethacin</td>
			<td>Merck/Sigma</td>
			<td>I7378</td>
			<td>For platelet isolation</td>
		</tr>
		<tr>
			<td>Micropipettes DURAN 50&#181;l</td>
			<td>Noxygen Science trasfer and Diagnostics GmbH</td>
			<td>NOX-G.6.1-50&#181;L</td>
			<td>Consumable for EPR</td>
		</tr>
		<tr>
			<td>Poly-L-lysine hydrochloride</td>
			<td>Merck/Sigma</td>
			<td>P2658</td>
			<td>For &#956;-slide coating</td>
		</tr>
		<tr>
			<td>Prostaglandin E1 (PGE1)</td>
			<td>Merck/Sigma</td>
			<td>P5515</td>
			<td>For platelet isolation</td>
		</tr>
		<tr>
			<td>Sodium citrate (4% w/v solution)</td>
			<td>Merck/Sigma</td>
			<td>S5770</td>
			<td>For platelet isolation</td>
		</tr>
		<tr>
			<td>Stirring bars (Teflon-coated)</td>
			<td>Labmedics/Chronolog</td>
			<td>P/N 313</td>
			<td>Consumable for incubation in aggregometer</td>
		</tr>
		<tr>
			<td>Superoxide dismutase&#8211;polyethylene glycol (PEG-SOD)</td>
			<td>Merck/Sigma</td>
			<td>S9549</td>
			<td>Superoxide anion scavenger (specificity control)</td>
		</tr>
		<tr>
			<td>Thrombin from human plasma</td>
			<td>Merck/Sigma</td>
			<td>T6884</td>
			<td>For platelet stimulation and &#956;-slide coating</td>
		</tr>
		<tr>
			<td>VAS2870</td>
			<td>Enzo Life Science</td>
			<td>BML-EI395</td>
			<td>NOX inhibitor</td>
		</tr>
		<tr>
			<td>Zeiss 510 LSM confocal microscope</td>
			<td>Zeiss</td>
			<td>NA</td>
			<td>Confocal microscope</td>
		</tr>
	</tbody>
</table>

alternative methods for the detection of superoxide anion generation in platelets 

Reactive oxygen species (ROS) are highly unstable oxygen-containing molecules. Their chemical instability makes them extremely reactive and gives them the ability to react with important biological molecules such as proteins, nucleic acids, and lipids. Superoxide anions are important ROS generated by the reduction of molecular oxygen reduction (i.e., acquisition of one electron). Despite their initial implication exclusively in aging, degenerative, and pathogenic processes, their participation in important physiological responses has recently become apparent. In the vascular system, superoxide anions have been shown to modulate the differentiation and function of vascular smooth muscle cells, the proliferation and migration of vascular endothelial cells in angiogenesis, the immune response, and the activation of platelets in hemostasis. The role of superoxide anions is particularly important in the dysregulation of platelets and the cardiovascular complications associated with a plethora of conditions, including cancer, infection, inflammation, diabetes, and obesity. It has, therefore, become extremely relevant in cardiovascular research to be able to effectively measure the generation of superoxide anions by&#160;human platelets,&#160;understand the redox-dependent mechanisms regulating the balance between hemostasis and thrombosis and, eventually,&#160;identify novel pharmacological tools for the modulation of platelet responses leading to thrombosis and cardiovascular complications. This study presents three experimental protocols successfully adopted for the detection of superoxide anions in platelets and the study of the redox-dependent mechanisms regulating hemostasis and thrombosis: 1) dihydroethidium (DHE)-based superoxide anion detection by flow cytometry; 2) DHE-based superoxide anion visualization and analysis by single platelet imaging; and 3) spin probe-based quantification of superoxide anion output in platelets by electron paramagnetic resonance (EPR).

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research

Alternative Methods for the Detection of Superoxide Anion Generation in Platelets 

The scope of our research is to understand how the generation of reactive oxygen species, regulates platelet function and modulates the hemostatic response. For our work, it is essential to reliably detect the key reactive oxygen species, superoxide anion. The most common technique to detect superoxide anion is flow cytometry with DCFDA as fluorescent probe.These as limitations, it induces the release of reactive oxygen species leading to unreliable data. It does not allow to distinguish, between different reactive oxygen species, and it does not allow to quantify platelet reactive oxygen species. This video presents two alternative techniques for the detection of platelet superoxide anions.The first technique utilizes DHE on live platelets to detect superoxide anion with fast kinetics and single-cell resolution. The second technique utilizes the spin probe, CMH, to quantify the rate of superoxide anion generation by platelets. Overall, the techniques presented in this video, offer significant advantages over most existing techniques, and represent a significant advance in the experimental tools at our disposal to study the redux-dependent regulation of platelets.

For flow cytometry detection of DHE fluorescence, we show representative results for platelets either resting (Figure 3A) or stimulated with 0.1 unit/mL thrombin (Figure 3B). The O2&#8226;- output was quantified as platelet mean fluorescence intensity (MFI), as shown for stimulation with 0.1 unit/mL thrombin (Figure 3C) or 3 &#181;g/mL collagen-related peptide (CRP) (Figure 3D</s...

Read this Scientific Article Protocol about Alternative Methods for the Detection of Superoxide Anion Generation in Platelets at JoVE.com

The generation of superoxide anion is essential for the stimulation of platelets and, if dysregulated, critical for thrombotic diseases. Here, we present three protocols for the selective detection of superoxide anions and the study of redox-dependent platelet regulation.

Reactive oxygen species (ROS) are highly unstable oxygen-containing molecules. Their chemical instability makes them extremely reactive and gives them the ...

alternative-methods-for-detection-superoxide-anion-generation

Research

JoVE Journal

Immunology and Infection

459 次观看.  South Mimms laboratories. 我们的研究范围是了解活性氧的产生如何调节血小板功能和调节止血反应。在我们的工作中，可靠地检测关键的活性氧物质——超氧阴离子至关重要。检测超氧阴离子的最常见技术是使用 DCFDA 作为荧光探针的流式细胞术。这些作为限制，它会诱导活性氧的释放，从而导致数据不可靠。它不允许区分不同的活性氧，也不允许量化血小板活性氧。?...

视频: 作者聚焦：ROS 检测的创新技术及其对血小板研究的影响

Detection of Superoxide Anion Using DHE by Single-Platelet Fluorescence Imaging

To begin, prepare the appropriate coating solution in modified Tyrode's buffer and coat an eight-well microslide by incubating it for two hours at 37 degrees Celsius. Then wash the coated microslide twice with modified Tyrode's buffer. Incubate the microslide in modified Tyrode's buffer containing five milligrams per milliliter BSA for at least 30 minutes to quench nonspecific adhesion.To prepare washed platelets, centrifuge citrate anticoagulated whole blood at 200 G for 20 minutes to obtain platelet-rich plasma. Then add indomethacin and PGE1 to the platelet-rich plasma and centrifuge at 500 G for 10 minutes. Resuspend the resulting platelet pellet in modified Tyrode's HEPES buffer at 37 degrees Celsius to achieve a density of four times 10 to the power of seven platelets per milliliter.Allow the isolated platelets to rest for 30 minutes at 37 degrees Celsius. Next, add DHE solution to the platelet suspension to achieve a final concentration of 10 micromolar and incubate at 37 degrees Celsius for one minute. After incubation, remove the blocking solution from the microslide and position it on the microscope stage for imaging.Then gently dispense the platelets. Use a 40X oil immersion lens on an inverted confocal microscope to monitor the conversion of DHE to 2-hydroxyethidium. Image for 10 minutes, collecting images every 10 seconds.To monitor superoxide anion generation in response to an agonist, add a soluble agonist 10 minutes after dispensing the platelets and collect fluorescence images for an additional 10 minutes. Using this protocol, the generation of superoxide radicals was studied during platelet adhesion to collagen or fibrinogen, and from platelets adhered to PLL stimulated with thrombin.

Detection Of Superoxide Anion in Platelets Using Electron Paramagnetic Resonance

To begin, obtain platelet-rich plasma by centrifuging the citrate anticoagulated whole blood at 200g for 20 minutes. Add indomethacin and PGE1 to the plasma and centrifuge at 500g for 10 minutes. Resuspend the resulting platelet pellet in modified Tyrode's HEPES buffer at 37 degrees Celsius to obtain a density of 2x10^8 platelets per milliliter.Rest the platelets for 30 minutes at 37 degrees Celsius. Add DETC to a final concentration of five micromolar and deferoxamine to a final concentration of 25 micromolar into the platelet suspension, followed by CMH to a final concentration of 200 micromolar. Place the samples into aggregation cuvettes equipped with Teflon-coated stirring magnets, and load them onto the aggregometer.After one minute, add stimuli such as thrombin or collagen, and incubate for 10 minutes. After incubation, transfer the platelet suspension from the aggregation cuvette to a micro centrifuge tube and quickly spin down at 6, 000g for 10 seconds. Load 50 microliters of the supernatant in capillary micro pipettes and seal with EPR sealing wax.Transfer samples to the EPR scanner and set the parameters on the scanner. Estimate CMH oxidation to CM radical as the area under the curve of the recorded EPR peaks. Obtain a calibration curve using commercially available CM radical.The EPR signal intensity in the samples was proportional to the intensity of the EPR peaks. The specificity of detection was confirmed with ROS scavengers and selective inhibitors of enzymes generating superoxide anion. Data for platelet stimulation with thrombin or collagen in the presence of the selective inhibitor VAS2870 suggested that NADPH oxidases are the main source of platelet superoxide anions in response to both these agonists.